K12 Digital Communications Drive Better Connections

 

On this episode of MarketScale’s EdTech podcast, host JW Marshall met Jo Webber, Chairman of the Board of Edlio, a provider of digital communications for K12 schools. The company works with public, private, and charters schools, counting over 15,000 customers.

The discussion, which occurred during the TCEA Convention in Austin in February, about using digital communications to connect teachers, students, and parents, is even more relevant now. Websites are a standard part of a school’s digital presence, but they have evolved immensely.

Jo said, “When we were just starting out, having a website was like a door sign. It was nothing more than one-way communication. Now, we’ve progressed to a two-way conversation.”

Students are now always connected to their technology. They are digital natives that respond better to digital forms of communication, and their parents may as well. While Edlio delivers easy to create and manage websites, they’ve taken their platform further with Edlio Engage, which was designed for educators and families to be engaged and communicate. It even includes shared calendars, volunteer management, and event signups.

It’s also helping overcome communication barriers, specifically parents that aren’t native English speakers. “The platform accounts for over 100 different languages that can be translated. A teacher writes an email in English, and it translates to the preferred language. Then the response from the parent is translated back to English,” Jo shared.

Having this clear communication and education can drive better outcomes for all parties, ensuring everyone is on the same page and involved.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More